



Dr. Ahmed A. Elberry, MBBCH, MSc, MD Assistant Professor of Clinical Pharmacology, Faculty of Medicine, BSU

DEFINITION & EPIDEMIOLOGY

• Def.:

 Inability of the heart to pump sufficient blood to meet the metabolic needs of the body.

HF can result from any disorder that reduces

- 1. Ventricular filling (diastolic) and/or
- 2. Myocardial contractility <u>(systolic</u>).




• Epidemiology:


- 0.3- 2% of general population & increase with age:
 - 3–5% in > 65 years old,
 - 8 16% in > 75 years.
- More in men, elderly, and black
- Mortality is high (8-year survival rate 15%)

Pathogenesis & Compensatory mechanisms in HF


- Structural changes:
 - Remodeling (Dilatation, Hypertrophy)
- Neurohumoral changes:
 - **1. ↑** Sympathetic nervous system. Leading to:
 - ↑ H.R & Contractility
 - VC:
 - Arterio- constriction → maintains arterial BI Pr
 - Veno- constriction → maintain venous return
 - remodeling
 - 2. ↑ RAAS leading to:
 - VC
 - \uparrow Aldosterone \rightarrow salt & H₂O retention \rightarrow \uparrow blood volume
 - Remodeling
 - \uparrow Endothelin secretion \rightarrow VC
 - 3. ↑ Natriuretic peptides (esp. BNP)
 - VD, natriuretc & diuretic effect
 - antagonize sympathetic outflow, RAAS & endothelin
 - Metabolized by Nebrilysin



Normal heart



Hypertrophied heart (diastolic heart failure)





Dilated heart (systolic heart failure)


Classification of HF

• Which side of heart is affected

- Left (more common)
- Right (right-sided MI, pulmonary HTN)
- Which heart <u>function</u> is affected
 - Systolic (HF with reduced LVEF): ↓ contraction & EF (below 40%), dilated LV
 - Diastolic (HFPEF): ↓ relaxation → Failure of LV filling (but contractile function & EF usually normal 50-70%)







Classification of Heart Failure ACC/AHA Staging v/s NYHA Functional Class

NYHA Functional Class
None
Asymptomatic
II Symptomatic with moderate exertion
III Symptomatic with minimal exertion
IV Symptomatic at rest

Causes of heart failure

Disease affecting heart

↑ Afterload

- 1- Volume overload
 - rapid infusion
 - Drugs: eg cortisone, licorice ..
- 2- Aortic or mitral valve defects

- 1- Cardiomyopathy
- 2-<u>IHD</u>
- 3- Arrhythmia
- 3-Infection
- 4- Drugs (cardiotoxic & -ve inotropic drugs)

1- Hypertension

2- Aortic stenosis

- Hypertension & IHD are the major causes
- Anemia & hyperthyroidism may cause high-output HF (uncommon)

Manifestations of HF


Signs Symptoms Related to \downarrow CO Related to + CO • • 1. Fatigue 1. Confusion Confusion 2 2. Sinus tachycardia 3. Angina **Related to fluid overload (congestion)** • DOE (shortness of breath) 1. Orthopnea 2. 2. Ascites 3. Cough 3. Peripheral edema 4. peripheral edema

-5. weight gain

3. Peripheral VC (cool, pale)

Related to fluid overload

- 1. Pulmonary edema
- 4. Elevated JVP





www.clinicalexams.co.uk

Diagnosis of HF



1. Clinically: symptoms & signs

2. Immaging:

- 1. Chest X-ray &
- 2. Echocardiogram (THE MOST USEFUL)

3. ECG

4. Laboratory: BNP (more than 200 pcg/L)

5. Invasive: Cardiac catheterization

Treatment of HF

Goal of therapy:


- 1. Ameliorate symptoms,
- 2. Avoid complications such as arrhythmias,
- 3. Improve the quality of life
- 4. Prolong survival.

Treatment lines:

1. Life style changes:

- ↓ 1- Fluid intake, 2- ↓ Dietary sodium, 3- ↓ weight
- Moderate exercise
- 2. Pharmacological:
 - ACEi, Diuretics, BB, digitalis & spironolactone
- 3. Devices:
 - CRT (Cardiac resynchronization therapy)
- 4. Surgical:
 - cardiac transplant

Drug treatment in heart failure



Drug treatment in heart failure

• Drugs that decrease the load on heart:

- Vasodilators1. mainly ACE inhibitors
 - 2. Others: Nitrates, Hydralazine & Nitroprusside
 - 3. Nesiritide (Natrecor):
 - it is a recombinant form of BNP
 - used IV in acute HF with dyspnea
 - 4. Sacubitril:
 - Nebrilysin inhibitor used with Valsartan (Enteresto) in ttt of CHF
 - 5. Bosentan: endothelin receptor antagonist
- 2. Diuretics (Loop Thiazide)
- 3. Aldosterone antagonist: Spironolactone
- **4.** BB

1.

Inotropic drugs:

- 1. Aminophylline
- **2. B**ipyridine [Inamrinone & Milrinone]
- **3. B** -agonist [Dopamine & Dobutamine]
- 4. Cardiac glycosides (digitalis)



	Stage A	Stage B	Stage C	Stage D
Manifestat ion	High risk pt.with no structural disease or symptoms	Structural heart disease with no symptoms	Structural heart disease with symptoms	Refractory heart failure
Therapy	 Treat predisposing factors Use ACE.I in appropriate pt. (DM, atherosclerosis) 	 ACE.I + BB 	 ACE.I + BB + Diuretics ± Digitalis Aldosterone antagonist CRT 	 All previous measures+ Continuous IV inotropics+ Heart transplantation

ACE Inhibitors

• Indication: Should be used in <u>all</u> stages of HF

• benefits:

- 1. Improve symptoms & decrease mortality (25%)
- 2. Slow disease progression
- 3. Reduce remodeling

• ACE-i Dosing Guidelines

	Initial	Target
Captopril	6.25 / 8h	50 / 8h
Enalapril	2.5 / 12 h	10 / 12h
Fosinopril	5 to 10 / day	40 / day
Lisinopril	2.5 to 5.0 / day	20 - 40 / day
Quinapril	10 / 12 h	20 - 40 / 12 h
Ramipril	1.25 to 2.5 / day	5 / 12 h

ARBs

Indications:

- In patients who are intolerant of ACE inhibitors
- Candesartan, 4-8 mg once daily initially; target dose, 32 mg once daily.
- Valsartan, 20- 40 mg twice daily initially; target dose, 160 mg twice daily.
- 🗸 Losartan: 25-50 mg once daily; target 100 mg once daily





β*-Blockers*

Beneficial effects may result from:

- 1. Improve symptoms & ↓ mortality (35%)
- 2. \checkmark <u>a</u>rrhythmic,
- 3. \blacklozenge heart rate \blacklozenge \blacklozenge myocardial O₂ demand,
- 5. \bullet renin release.
- 6. \blacksquare myocyte <u>d</u>eath from catecholamine-induced necrosis

Indication:

- <u>All stable patients</u> with HF (at least 2 w.) & + LVEF in the absence of C.I
 - <u>NB.</u>: stable: Not receiving <u>IV</u> inotropic or <u>IV</u> diuretic therapy,
 - without significant peripheral & pulmonary cong.

 \mathbf{H} addition of βB is likely to be of greater benefit than $\mathbf{\uparrow}$ ACEI dose

 βB may cause acute + in LVEF & short-term worsening of HF symptoms on initiation & at each dosage titration.

βB Dosing

- βB should be started in very low doses with slow titration
- Doses is doubled every 2-4 weeks

	Starting Dosage	Target Dosage
Carvedilol	3.125 mg BID	25 mg BID
Bisoprolol	1.25 mg/day	10 mg/day
Metoprolol succinate XL	12.5–25 mg/day	200 mg/day

• NB.:

- higher βB doses are associated with ↑ reduction in mortality. Therefore, if hypotension alone is the problem, try reducing the dose of the ACEI first.
- Carvedilol may be preferred esp if associated with hypertension??, but not preferred if EF less than 20

Diuretics in HF

Indications:

• Symptomatic HF with evidence of fluid retention (edema)

• Benefits:

- Improve symptoms (No benefit on mortality)
- **NB.:** Never use as the only therapy for HF (no effect on progression or mortality)

	Furosemide (lassix)	Bumetanide	Torsemide
Usual daily dose (oral)	20–160 mg/day	0.5–4 mg/day	10–80 mg/day
Maximum daily dose	600	10	200
Ceiling dose*:			
Normal renal function	80–160 mg	1–2 mg	20–40 mg
CL _{cr} : 20–50 mL/min	160 mg	2 mg	40 mg
CL _{cr} : <20 mL/min	400 mg	8–10 mg	100 mg

*Ceiling dose: single dose above which additional response is unlikely to be observed.

• Thus, once reached, more frequent dosing should be used for additional effect, rather than giving higher doses.

Choosing diuretic:

- Loop diuretic is usually preferred over THZ (why???)
- THZ is indicated in:
 - Combination with loop to enhance the effect of loop
 - Mild fluid retention with HTN (THZ is preferred)
 - NB.: Metolazone is often used in
 - Compromised renal function (Cl_{Cr} < 30 mL/min) instead of Hydrochlorthiazide
 - Combination with loop diuretics when patients exhibit *diuretic resistance* (edema unresponsive to loop diuretics alone).

Aldosterone Antagonists

• Include: Spironolactone & eplerenone

- Benefit: comes from aldosterone antagonist rather than diuretic effect
 - Improve symptoms & decrease mortality (30%)

Indications:

 patients with moderate to severe HF (class III and IV) who are receiving standard therapy

• Dosing:

- Initial doses should be low (spironolactone 12.5 mg/day; eplerenone 25 mg/day), especially:
 - Elderly
 - Diabetes
 - Creatinine clearance <50 mL/min.
- Side effects:
 - Hyperkalemia & Gynecomastia (see HT)



Digitalis




Indications

- 1. When no adequate response to ACE-i + BB + diuretics
- 2. Supraventricular arrhythmia, to slow AV conduction
- Benefits: Improve symptoms (No benefit on mortality)

• Dose 0.125 to 0.250 mg / day

Mechanism:



SE of digitalis

1. <u>Narrow safety margin (Low therapeutic index):</u>

- 1. Therapeutic level for digoxin: 0.5-2 ng/ml
- 2. Toxic level: more than 2 ng/ml

2. Early manifestation of toxicity:

- 1. Anorexia nausea vomiting
- 2. Bradycardia < 60 beat /min.





3. Late manifiatation of toxicity:

- **1.** C.V.S: Bradycardia HB Ventricular arrhythmia
- 2. G.I.T: Anorexia Nausea Vomiting Colic Diarrhea
- C.N.S: Headache Hallucination Delirium Confusion
 Convulsions
- 4. Eye: visual disturbance & colored vision [yellow or green] (Chromatopsia)
- 5. Skin: Allergy
- 6. Hormonal: Gynecomastia (rare)

4) Treatment of digitalis toxicity

1.Stop digitalis & K⁺- depleting diuretics

- 2.KCI → Oral or I.V infusion with ECG monitoring, <u>IF</u> plasma K⁺ is low or normal
 & provided <u>no</u> HB <u>or</u> RF
 - <u>NB.</u>: In severe digitalis toxicity, serum K⁺ will be already elevated (due its loss from tissues)



- 3. Digitalis antibodies (digoxin immune fab IV) (digibind, digifab)
- 4. Treatment of arrhythmia:
 - 1. O₂ [as ischemia favors arrhythmia]
 - 2. If bradycardia or H.B <u>only</u> → Atropine
 - 3. If arrhythmia <u>+</u> H.B → Phenytoin [Drug of choice] or Lidocain

<u>N.B.</u>: No need for stomach wash

Drugs that may increase Digitalis toxicity

- Sympathomimetic B₁ agonist: [Adr. Isoprenaline-Ephedrine] → Arrhythmia
- 2. Sympatholytic BB: [Propranolol] → severe H.B
- Parasympatholytic [Atropine] → ↓ gastric emptying → ↑ absorp. & toxicity
- 4. Calcium I.V
- 5. Calcium channel blockers: [Verapamil] → severe H.B
- 6. Quinidine \rightarrow displaces Digitalis & \downarrow Excretion
- 7. Thyroxin → arrhythmia
- 8. Hypokalemia induced by some drugs as: K⁺ depleting diuretic [Thiazide & Loop] – Cortisone – Carbenoxolone

Digitalis Contraindications

- 1. Hypersensitive carotid sinus or bradycardia
- 2. Advanced A-V block
- 3. Ventricular arrhythmia
- 4. W-P-W with atrial fibrillation
- 5. Obstructive cardiomyopathy $\rightarrow \downarrow CO$
- 6. Marked Hypokalemia

Acute pulmonary edema (acute HF)

- 1- Asses/treat arrhythmia or acute coronary syndrome
- 2- 02
- 3- IV diuretic (furosemide 50 mg)
- 4- IV opiate + antiemetic (4-8 mg morphine + 10 mg metoclopromide)

If hypotension or shock

5- IV inotrpics (milrinon, dobutamine, dopamine)

If inadequate response

6- IV vasodilators (NTG, Nitroprusside, Nesiretide)

Inamrinone & Milrinone

- <u>Mechanism of action</u>: \downarrow PDE enzyme type 3 \rightarrow \uparrow c.AMP \rightarrow inodilators:
 - +ve inotropic effect
 - Mixed V.D [artery & Vein] → ↓ preload & after load

<u>Side effects:</u>

- 1. Bone marrow toxicity → Thrombocytopenia
- 2. Hepatotoxicity
- 3. $\uparrow O_2$ consumption \rightarrow worsens angina

• <u>Uses:</u>

• I.V as short term therapy in acute heart failure

• <u>N.B</u>: Milrinone as Inamrinone but differs in:

- 1. Less side bone marrow depression & hepatotoxicity, but
- 2. More liable to cause arrhythmia


Cardiac resynchronization therapy (CRT)


• CRT

• is the use of cardiac pacing to coordinate the contraction of the left & right ventricles.

Indicated in patients:

- Receiving optimal HF standard medical therapy +
- 2. LVEF ≤35% +
- electric asynchrony shown by wide QRS (>120 milliseconds)







Animation New therapy prevents heart failure.flv

GOODLUCK

berry_ahmed@yahoo.com